TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard...
From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals...
AACR Annual Cancer Progress Report Highlights Scientific Advances Against Cancer, Challenges and Opportunities Ahead
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)...
Value of Some Established Treatment Practices in Chronic Myeloid Leukemia
The introduction of imatinib mesylate, the first BCR::ABL1 tyrosine kinase inhibitor, as a treatment of Philadelphia chromosome (Ph)-positive chronic myeloid leukemia...
Two Studies Show Improved Survival With Novel Front-Line Combinations in Advanced Urothelial Carcinoma
Two phase III trials presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress 2023 showed an overall survival...
Richard J. Boxer, MD, FACS: The Future Priorities of the National Cancer Institute
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
William J.M. Hrushesky, MD, FACP, ABIM IM & MO: Perspectives on Cancer Therapy Development
Nagi El Saghir, MD, FACP, FASCO: On the Art of Organizing Best of ASCO Meetings
Noelle K. LoConte, MD: ‘I Want to Kill You’
Sponsored Content
SPONSORED BY AVEO ONCOLOGY, an LG Chem Company
Treatment Sequencing for Relapsed or Refractory Renal Cell Carcinoma: Considerations in an Evolving Landscape
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed or Refractory Mantle Cell Lymphoma
Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy
As reported in the Journal of Clinical Oncology and during the 2021 ASCO Annual Meeting by Ingrid A. Mayer, MD, and colleagues, the phase III ECOG-ACRIN EA1131 trial investigated the use of adjuvant platinum vs capecitabine in patients with basal subtype triple-negative breast cancer and residual...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML
As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
